pharmatimes.com Report : Visit Site

Technical data of the pharmatimes.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host pharmatimes.com. Currently, hosted in United Kingdom and its service provider is Squiz UK Limited .

the related websites

usclinicalresearcher.com edition.pagesuite-professional.co.uk chiltern.com iconplc.com binleys.com newsnow.co.uk omniamed.co.uk justpharma.co.uk dailymail.co.uk reel-estates.co.uk ticketmaster.com thepowerof10.info bbc.co.uk ubuntu.com pressvess.co.uk warriorcats.com neff.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called openresty/1.11.2.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- -- subscribe advertise about us -- -- go magazine web exclusives news competitions events -- knowledge centre -- appointments jobs business insights webinars thought leadership magazine overview latest issue business insights subscribe have your say media information magazine archive news news free news subscriptions free rss feed competitions overview marketer marketer of the year overview how the competition works categories enter nominate steering group become a judge testimonials gallery alumni latest news sponsors sponsorship opportunities contact us communications team communications team of the year overview how the competition works categories enter nominate steering group become a judge testimonials gallery alumni latest news sponsors sponsorship opportunities contact us international clinical researcher international clinical researcher of the year overview categories how it works attend enter nominate executive steering group alumni finalists 2018 winners 2018 gallery videos testimonials sponsorship opportunities sponsors supporters latest news terms & conditions privacy policy contact us clinical researcher - the americas clinical researcher of the year - the americas overview how the competition works categories attend enter executive steering group alumni finalists 2018 winners 2018 gallery videos testimonials tickets sponsorship opportunities sponsors latest news terms & conditions privacy policy contact us sales awards sales awards overview how the competition works categories enter nominate steering group latest news sponsors contact us medical & scientific excellence awards medical & scientific excellence awards overview how the competition works categories enter nominate steering group sponsorship opportunities contact us appointments jobs business insights webinars -- subscribe advertise about us -- health apps: working smarter, not just harder the myriad ways digital tools could change everything for pharma and the nhs 9th july 2018 -- health apps: the litmus test our mobile health is on a mission to build confidence in digital health by assessing and curating high-quality health apps. ceo julie bretland tells us what the company looks for in a good app and how digital health can change the industry 9th july 2018 july/august issue out now! feat.: making health apps a reality; brexit and the supply chain; patiet-centric sales -- -- medical affairs: the navigator of pharma’s new world order why medical affairs is the most important role in the future of pharma 9th july 2018 -- the biosimilars era biosimilars may have proven their worth, but how can adoption be sped up? 24th may 2018 -- on the comms radar pharma comms is one of the most dynamic sectors of the industry. so, what should be on communicators’ radar? 24th may 2018 news view all roche’s antiviral hits flu targets in phiii trial roche says its investigational flu drug baloxavir marboxil, in-licensed from japan’s shionogi, has met key goals in a late-stage trial. 17th july 2018 roche’s antiviral hits flu targets in phiii trial roche says its investigational flu drug baloxavir marboxil, in-licensed from japan’s shionogi, has met key goals in a late-stage trial. -- roche’s antiviral hits flu targets in phiii trial roche says its investigational flu drug baloxavir marboxil, in-licensed from japan’s shionogi, has met key goals in a late-stage trial. -- pfizer kicks off phiii programme for haemophilia b gene therapy pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia b. 17th july 2018 pfizer kicks off phiii programme for haemophilia b gene therapy pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia b. -- pfizer kicks off phiii programme for haemophilia b gene therapy pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia b. -- uk panel says human embryo editing ‘morally permissible’ an independent ethics panel in the uk has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”. 17th july 2018 uk panel says human embryo editing ‘morally permissible’ an independent ethics panel in the uk has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”. -- uk panel says human embryo editing ‘morally permissible’ an independent ethics panel in the uk has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”. -- nice issues cerebral palsy guideline for adults the national institute for health and care excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy. 17th july 2018 nice issues cerebral palsy guideline for adults the national institute for health and care excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy. -- nice issues cerebral palsy guideline for adults the national institute for health and care excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy. -- eu approval for akcea/ionis’ rare disease therapy european regulators have approved akcea and ionis’ tegsedi for patients with hereditary transthyretin amyloidosis (hattr), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs. 17th july 2018 eu approval for akcea/ionis’ rare disease therapy european regulators have approved akcea and ionis’ tegsedi for patients with hereditary transthyretin amyloidosis (hattr), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs. -- eu approval for akcea/ionis’ rare disease therapy european regulators have approved akcea and ionis’ tegsedi for patients with hereditary transthyretin amyloidosis (hattr), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs. -- top trending pfizer re-organises into three business units medical affairs: the navigator of pharma’s new world order magazine july 2018 nice turns down darzalex combo for pre-treated multiple myeloma janssen launches phii/iii programme testing tremfya in crohn’s gsk sells psoriasis/dermatitis therapy to dermavant europe recalling some valsartan meds on safety fears web exclusives view all is data holding you back? how data trends in the financial services sector could transform pharma medtech: challenges of a healthcare revolution a new report looks into how medtech must address key problems medical data and the rise of blockchain blockchain technology could be game-changing for electronic medical records, but new gdpr rules need to be taken into account value-based healthcare: matching who benefits with who pays seeking success in value-based healthcare magazine view more from the latest edition patient files: chronic myeloid leukaemia katie ruane was just 22 when diagnosed with cml, and while drugs keep the disease in remission it still takes a huge toll on her life putting our heads together nhs england’s assurance process provides a window of opportunity for pharma – but communication and joint working with the health service is key the dementia dilemma the failure of several alzheimer’s drug trials in the past year has dampened, but not destroyed, hopes for a cure genome sequencing: unlocking personalised medicine home dna tests are now common, but using genome sequencing to personalise drugs still has some way to go how brexit will impact the supply chain the regulatory impacts of brexit

URL analysis for pharmatimes.com

http://www.pharmatimes.com/news/roches_antiviral_hits_flu_targets_in_phiii_trial_1244536
http://www.pharmatimes.com/appointments
http://www.pharmatimes.com/clinical_researcher_americas/terms_and_conditions
http://www.pharmatimes.com/magazine/2018/julyaugust_2018/patient_centricity_through_the_shop_window
http://www.pharmatimes.com/medical_scientific_excellence_awards/overview
http://www.pharmatimes.com/sales_awards/steering_group
http://www.pharmatimes.com/marketer/become_a_judge
http://www.pharmatimes.com/clinical_researcher_americas/gallery
http://www.pharmatimes.com/marketer/nominate
http://www.pharmatimes.com/clinical_researcher_americas/executive_steering_committee
http://www.pharmatimes.com/magazine/2018/julyaugust_2018/medical_affairs_the_navigator_of_pharmas_new_world_order
http://www.pharmatimes.com/international_clinical_researcher/enter
http://www.pharmatimes.com/news/gsk_sells_psoriasisdermatitis_therapy_to_dermavant_1244163
http://www.pharmatimes.com/clinical_researcher_americas/latest_news
http://www.pharmatimes.com/international_clinical_researcher/finalists
edition.pagesuite-professional.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Whois Server Version 2.0

Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.

Domain Name: PHARMATIMES.COM
Registrar: TUCOWS DOMAINS INC.
Sponsoring Registrar IANA ID: 69
Whois Server: whois.tucows.com
Referral URL: http://www.tucowsdomains.com
Name Server: NS1.LIVEDNS.CO.UK
Name Server: NS2.LIVEDNS.CO.UK
Name Server: NS3.LIVEDNS.CO.UK
Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Updated Date: 21-feb-2017
Creation Date: 23-mar-2000
Expiration Date: 23-mar-2018

>>> Last update of whois database: 2017-07-23T08:00:47Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR TUCOWS DOMAINS INC.

  REFERRER http://www.tucowsdomains.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =pharmatimes.com

  PORT 43

  SERVER whois.tucows.com

  ARGS pharmatimes.com

  PORT 43

  TYPE domain

DOMAIN

  NAME pharmatimes.com

NSERVER

  NS1.LIVEDNS.CO.UK 213.171.192.250

  NS2.LIVEDNS.CO.UK 213.171.193.250

  NS3.LIVEDNS.CO.UK 213.171.192.254

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2017-02-21

  CREATED 2000-03-23

  EXPIRES 2018-03-23

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .